SCHEMBL19089782

SCHEMBL19089782

CC(=O)NCCc1ccc(NC(=O)OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
KDM4E B2RXH2 1/20 0.54
F13A1 P00488 1/20 0.54
MAPT P10636 3/20 0.53
TP53 P04637 1/20 0.53
KDM1A O60341 2/20 0.52
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
RECQL P46063 1/20 0.51
MGLL Q99685 1/20 0.51
ROCK2 O75116 1/20 0.51
RCOR1 Q9UKL0 1/20 0.51
TGM2 P21980 1/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL590420 0.83 POLB (0.62) POLBMAPTTP53KDM1AMAOA
SCHEMBL23917849 0.83 ALDH1A1 (0.69) POLBMAPTTP53KDM1AMAOA
SCHEMBL5582508 0.83 POLB (0.58) POLBMAPTTP53KDM1AMAOA
SCHEMBL8867533 0.82 POLB (0.64) POLBMAPTTP53KDM1AMAOA
SCHEMBL3968088 0.82 POLB (0.64) POLBMAPTTP53KDM1AMAOA
SCHEMBL21054940 0.81 POLB (0.62) POLBMAPTTP53KDM1AMAOA
SCHEMBL19682897 0.81 POLB (0.62) POLBMAPTTP53KDM1AMAOA
SCHEMBL592715 0.80 POLB (0.66) POLBMAPTTP53KDM1AMAOA
SCHEMBL27475998 0.80 KDM4E (0.49) KDM4EF13A1MAPTMEN1KMT2A
SCHEMBL8428000 0.80 LMNA (0.69) MAPTMEN1KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066526-B2 Method for cleaving amide bonds Galderma Holding SA (CH) 2021-07-20 US disclosed
US-11066526-B2 Method for cleaving amide bonds Galderma Holding SA (CH) 2021-07-20 US disclosed
US-10954316-B2 Method for cleaving amide bonds Galderma Holding SA (CH) 2021-03-23 US disclosed
US-20190010113-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2019-01-10 US disclosed
WO-2017207564-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2017-12-07 WO disclosed
WO-2017114859-A1 METHOD FOR CLEAVING AMIDE BONDS GALDERMA S.A. (CH) 2017-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010113-A1 METHOD FOR CLEAVING AMIDE BONDS DNPEP, NAAA, ASPH POLB 1122/4885KDM4E 1693/4885F13A1 1144/4885
US-11066526-B2 Method for cleaving amide bonds DNPEP, NAAA, ASPH POLB 1122/4885KDM4E 1693/4885F13A1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.